Abstract 2287P
Background
Antibody titers after two doses of mRNA-based SARS-Cov-2 vaccines (SVC) decline after 6 months, requiring a further dose to boost immune response. Anticancer agents may differentially impact the response to SVC, but a direct comparison between patients and with healthy controls (HC) has not been conducted. We serially assessed the immunomic changes associated with the booster dose of SVC in patients treated with adjuvant chemotherapy (aCT, colorectal and breast cancer), rituximab (R, non-Hodgkin lymphoma), immune checkpoint inhibitors (ICI, solid tumors), and HC.
Methods
In the above mentioned groups, we performed blood transcriptome sequencing (TS), multiplex antibody titer (ABt, Spherotech), and SARS-CoV-2-specific IFN release assay (IGRA) before the third vaccine dose (TS/AT/IGRA), after 24 hours (TS), at 5 days (d - TS/IGRA), 26d (AT/IGRA) and after six months (mo - AT/IGRA). Immune transcriptomic modules were assessed using BloodGene3.
Results
We enrolled 52 subjects: 11 R, 11 ICI, 8 aCT, and 22 HC. aCT or ICI showed similar vaccine-specific ABt compared with HC at 26d, increasing at 6mo. ICI showed a significantly reduced increase of IgG2 vaccine-specific ABt at 26d compared with HC. R showed a blunted response at 26d. In all groups, the Env and Core ABt increased significantly at 6mo (81% of subjects), with symptomatic infection in only 31% of subjects. We observed a delayed (5d) but efficient increase in inflammation and chemochine modules in aCT, reduced early inflammation (24h) and increased delayed plasma-cell response (5d) in ICI, and reduced response to all immune modules, except for a delayed increase in IFN modules (5d), in R compared with HC. IGRA results were consistent with IFN modules, with a 5d increase in R.
Conclusions
Patients undergoing aCT and ICI mount a vaccine-mediated immunomic response in part similar, but not identical, to HC, and R patients show a blunted vaccine response in line with the literature. A large fraction of all enrolled subjects developed ABt against natural infection, in the absence of symptoms, at 6mo.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Policlinico San Martino, Genoa IT.
Funding
University of Genoa , 5x1000 IRCCS funds, AIRC, ACC.
Disclosure
G. Zoppoli: Financial Interests, Personal, Stocks or ownership: Immunomica Srl; Financial Interests, Personal, Invited Speaker: Novartis; Non-Financial Interests, Institutional, Product Samples: ThermoFisher Scientific; Non-Financial Interests, Personal, Other, Travel grant: Novartis, Roche. C. Genova: Financial Interests, Personal, Invited Speaker, Speaker's Bureau (scientific meeting): AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Eli Lilly, Novartis; Financial Interests, Personal, Advisory Board, Advisory board: Amgen, Sanofi; Financial Interests, Personal, Advisory Board, Advisory Board: Roche, Takeda; Financial Interests, Institutional, Funding, Funding for support of translational study: Bristol Myers Squibb; Financial Interests, Institutional, Funding, Funding in support of translational study: AstraZeneca; Financial Interests, Institutional, Research Grant, Research Grant for translational study: Italian Ministry of Health; Non-Financial Interests, Principal Investigator, Local PI for clinical trials: AstraZeneca, Roche; Non-Financial Interests, Member, Scientific Society Membership: ASCO, AIOM, FONICAP, AIOT, IASLC, ISLB. R. Lemoli: Financial Interests, Other: Jazz, Pfizer, AbbVie, BMS, Sanofi, StemLine. All other authors have declared no conflicts of interest.
Resources from the same session
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08